Literature DB >> 20219853

Role of the high mobility group A proteins in the regulation of pituitary cell cycle.

Monica Fedele1, Alfredo Fusco.   

Abstract

Pituitary cells are particularly sensitive to alterations of the cell cycle machinery. In fact, mutations affecting expression of proteins critical for cell cycle progression, including retinoblastoma protein, cyclins D1 and D3, p16(INK4A), and p27(kip1), are frequent in human pituitary adenomas. Similarly, both targeted disruption and overexpression of either cell cycle inhibitors or activators, respectively, lead to the development of pituitary adenomas in mice. Recent evidence has added the high mobility group A (HMGA) proteins as a new class of cell cycle regulators that play significant roles in the pathways that lead to pituitary tumor evolution in both humans and experimental animal models. Here, we first review the role of the cell cycle in pituitary tumorigenesis, as witnessed by human pathology and transgenic mice; and then, we focus on HMGA proteins and their cell cycle-related role in pituitary tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20219853     DOI: 10.1677/JME-09-0178

Source DB:  PubMed          Journal:  J Mol Endocrinol        ISSN: 0952-5041            Impact factor:   5.098


  17 in total

1.  Anterior pituitary adenomas: inherited syndromes, novel genes and molecular pathways.

Authors:  Paraskevi Xekouki; Monalisa Azevedo; Constantine A Stratakis
Journal:  Expert Rev Endocrinol Metab       Date:  2010-09-01

2.  The HMGA gene family in chordates: evolutionary perspectives from amphioxus.

Authors:  Matteo Bozzo; Simone Macrì; Daniela Calzia; Riccardo Sgarra; Guidalberto Manfioletti; Paola Ramoino; Thurston Lacalli; Robert Vignali; Mario Pestarino; Simona Candiani
Journal:  Dev Genes Evol       Date:  2017-05-04       Impact factor: 0.900

3.  Hormonal aggressiveness according to the expression of cellular markers in corticotroph adenomas.

Authors:  Jung Soo Lim; Mi-Kyung Lee; Eunhee Choi; Namki Hong; Soo Il Jee; Sun Ho Kim; Eun Jig Lee
Journal:  Endocrine       Date:  2018-11-24       Impact factor: 3.633

Review 4.  The High Mobility Group A1 (HMGA1) Transcriptome in Cancer and Development.

Authors:  T F Sumter; L Xian; T Huso; M Koo; Y-T Chang; T N Almasri; L Chia; C Inglis; D Reid; L M S Resar
Journal:  Curr Mol Med       Date:  2016       Impact factor: 2.222

5.  HMGA1-pseudogene expression is induced in human pituitary tumors.

Authors:  Francesco Esposito; Marco De Martino; Daniela D'Angelo; Paula Mussnich; Gerald Raverot; Marie-Lise Jaffrain-Rea; Filippo Fraggetta; Jacqueline Trouillas; Alfredo Fusco
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

6.  GSK3β activity is essential for senescence-associated heterochromatin foci (SAHF) formation induced by HMGA2 in WI38 cells.

Authors:  Xi Shi; Baoqing Tian; Chi Ma; Lingxia Liu; Na Zhang; Yuan Na; Jing Li; Jun Lu; Yuehua Qiao
Journal:  Am J Transl Res       Date:  2017-01-15       Impact factor: 4.060

Review 7.  Interplay between HMGA and TP53 in cell cycle control along tumor progression.

Authors:  Nathalia Meireles Da Costa; Antonio Palumbo; Marco De Martino; Alfredo Fusco; Luis Felipe Ribeiro Pinto; Luiz Eurico Nasciutti
Journal:  Cell Mol Life Sci       Date:  2020-09-12       Impact factor: 9.261

8.  HMGA2 cooperates with either p27kip1 deficiency or Cdk4R24C mutation in pituitary tumorigenesis.

Authors:  Monica Fedele; Orlando Paciello; Davide De Biase; Mario Monaco; Gennaro Chiappetta; Michela Vitiello; Antonio Barbieri; Domenica Rea; Antonio Luciano; Serenella Papparella; Claudio Arra; Alfredo Fusco
Journal:  Cell Cycle       Date:  2018-01-30       Impact factor: 4.534

9.  RPSAP52 lncRNA is overexpressed in pituitary tumors and promotes cell proliferation by acting as miRNA sponge for HMGA proteins.

Authors:  Daniela D'Angelo; Paula Mussnich; Romina Sepe; Maddalena Raia; Luigi Del Vecchio; Paolo Cappabianca; Simona Pellecchia; Sara Petrosino; Serena Saggio; Domenico Solari; Filippo Fraggetta; Alfredo Fusco
Journal:  J Mol Med (Berl)       Date:  2019-05-10       Impact factor: 4.599

Review 10.  Genetically engineered mouse models of pituitary tumors.

Authors:  David A Cano; Alfonso Soto-Moreno; Alfonso Leal-Cerro
Journal:  Front Oncol       Date:  2014-08-01       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.